Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this clinical trial was to evaluate the safety, reliability, and benefit of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) in restoring some visual function to subjects completely blind from RP. We report clinical trial results at 1 and 3 years after implantation.
Original Source [2]
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/long-term-results-epiretinal-prosthesis-restore-sight-blind
[2] http://www.aaojournal.org/article/S0161-6420(15)00415-7/abstract
[3] http://admin.indiaenvironmentportal.org.in/category/author/allen-c-ho
[4] http://admin.indiaenvironmentportal.org.in/category/author/mark-s-humayun
[5] http://admin.indiaenvironmentportal.org.in/category/author/jessy-d-dorn-et-al
[6] http://admin.indiaenvironmentportal.org.in/category/journal/ophthalmology
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/eye-diseases
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/blindness
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/united-states-america-us
